LENSAR

LENSAR Enterprise Value

The Enterprise Value (EV) of LENSAR (LNSR) as of Oct 20, 2026 is 128.85 M USD. In the previous year, Enterprise Value (EV) was 123.63 M USD — a change of 4.23% (higher).

Enterprise Value

128.85 MUSD

YoY

4.23%

Last updated:

Enterprise Value (EV) of LENSAR is 2025 128.85 M USD. Enterprise Value (EV) of LENSAR was 2024 123.63 M USD. It decreases by 4.23% higher compared to the previous year.

The LENSAR Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
183.95 M USD
Jan 1, 2019
198.09 M USD
Jan 1, 2020
105.48 M USD
Jan 1, 2021
114.44 M USD
Jan 1, 2022
131.41 M USD
Jan 1, 2023
122.02 M USD
Jan 1, 2024
123.63 M USD
Jan 1, 2025
128.85 M USD
The LENSAR Enterprise Value history
YEAREnterprise ValueYoY
128.85 MUSD+4.23%
123.63 MUSD+1.32%
122.02 MUSD-7.15%
131.41 MUSD+14.82%
114.44 MUSD+8.50%
105.48 MUSD-46.75%
198.09 MUSD+7.69%
183.95 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LENSAR Stock analysis

What does LENSAR do? LENSAR, Inc. generates revenue through the sale of its femtosecond laser systems, specifically the LENSAR Laser System with Streamline IV and IntelliAxis, and the ALLY Adaptive Cataract Treatment System. The LENSAR Laser System includes disposable patient interface device kits as consumables, which contribute to recurring revenue. Surgeons and ophthalmic clinics purchasing these systems form the primary customer segment, utilizing the technology for cataract surgery and corneal astigmatism management. The company's focus on proprietary technologies ensures differentiation in the medical device market. The ALLY System is marketed as a compact solution for femtosecond laser assisted cataract procedures, designed to streamline surgical workflows within a single operating room. Its product portfolio emphasizes integrated features that enhance visual outcomes for patients. The consumable components, such as the disposable patient interface device kits, support ongoing revenue streams alongside the initial system sales. These offerings target healthcare providers seeking advanced surgical tools for refractive cataract surgery. LENSAR's business model relies on selling high-precision medical devices to specialized healthcare facilities. The LENSAR Laser System and ALLY System are positioned as premium solutions for cataract treatment, with the consumables providing sustained revenue opportunities. The company's product development centers around improving surgical efficiency and patient visual results through its patented technologies. LENSAR is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LENSAR stock

Enterprise Value (EV) of LENSAR is 128.85 M USD in 2025.

Enterprise Value (EV) of LENSAR changed from 123.63 M USD to 128.85 M USD, representing a 4.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) LENSAR since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s LENSAR with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — LENSAR

All Key Metrics — LENSAR